Five-year surveillance of aminoglycoside usage in a university hospital

R. F. Betts, W. M. Valenti, S. W. Chapman, T. Chonmaitree, G. Mowrer, P. Pincus, M. Messner, R. Robertson

Research output: Contribution to journalArticle

64 Citations (Scopus)

Abstract

Because an increased incidence of nosocomial bacteremia due to gentamicin-resistant organisms occurred in our hospital, amikacin was substituted for gentamicin as the primary empiric aminoglycoside. Prospective surveillance of aminoglycoside use and of bacterial resistance to aminoglycoside was done before and after the substitution. We compared the baseline period with gentamicin was the primary aminoglycoside with the subsequent period when amikacin accounted for 81% of aminoglycoside used. During the two periods the patient population did not differ with regard to indications for aminoglycoside therapy. Among the gram-negative organisms isolated, rates of amikacin resistance during the baseline (1.1%) and usage (1.05%) periods were not significantly different (p > 0.6). Resistance to gentamicin and tobramycin during the period of amikacin use showed a statistically significant decrease (p > 0.001) due to decreased resistance to gentamicin of Providencia, Serratia, indole-positive Proteus, and decreased resistance to tobramycin of Pseudomonas aueruginosa. Unrestricted use of amikacin does not necessarily lead to increase in amikacin resistance but may lead to a decrease in resistance to gentamicin and tobramycin among gram-negative organisms.

Original languageEnglish
Pages (from-to)219-222
Number of pages4
JournalAnnals of Internal Medicine
Volume100
Issue number2
StatePublished - 1984
Externally publishedYes

Fingerprint

Amikacin
Aminoglycosides
Gentamicins
Tobramycin
Providencia
Serratia
Proteus
Bacteremia
Pseudomonas
Incidence
Population

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Betts, R. F., Valenti, W. M., Chapman, S. W., Chonmaitree, T., Mowrer, G., Pincus, P., ... Robertson, R. (1984). Five-year surveillance of aminoglycoside usage in a university hospital. Annals of Internal Medicine, 100(2), 219-222.

Five-year surveillance of aminoglycoside usage in a university hospital. / Betts, R. F.; Valenti, W. M.; Chapman, S. W.; Chonmaitree, T.; Mowrer, G.; Pincus, P.; Messner, M.; Robertson, R.

In: Annals of Internal Medicine, Vol. 100, No. 2, 1984, p. 219-222.

Research output: Contribution to journalArticle

Betts, RF, Valenti, WM, Chapman, SW, Chonmaitree, T, Mowrer, G, Pincus, P, Messner, M & Robertson, R 1984, 'Five-year surveillance of aminoglycoside usage in a university hospital', Annals of Internal Medicine, vol. 100, no. 2, pp. 219-222.
Betts RF, Valenti WM, Chapman SW, Chonmaitree T, Mowrer G, Pincus P et al. Five-year surveillance of aminoglycoside usage in a university hospital. Annals of Internal Medicine. 1984;100(2):219-222.
Betts, R. F. ; Valenti, W. M. ; Chapman, S. W. ; Chonmaitree, T. ; Mowrer, G. ; Pincus, P. ; Messner, M. ; Robertson, R. / Five-year surveillance of aminoglycoside usage in a university hospital. In: Annals of Internal Medicine. 1984 ; Vol. 100, No. 2. pp. 219-222.
@article{3bf63d0803be4bdaae84c1b98cce352e,
title = "Five-year surveillance of aminoglycoside usage in a university hospital",
abstract = "Because an increased incidence of nosocomial bacteremia due to gentamicin-resistant organisms occurred in our hospital, amikacin was substituted for gentamicin as the primary empiric aminoglycoside. Prospective surveillance of aminoglycoside use and of bacterial resistance to aminoglycoside was done before and after the substitution. We compared the baseline period with gentamicin was the primary aminoglycoside with the subsequent period when amikacin accounted for 81{\%} of aminoglycoside used. During the two periods the patient population did not differ with regard to indications for aminoglycoside therapy. Among the gram-negative organisms isolated, rates of amikacin resistance during the baseline (1.1{\%}) and usage (1.05{\%}) periods were not significantly different (p > 0.6). Resistance to gentamicin and tobramycin during the period of amikacin use showed a statistically significant decrease (p > 0.001) due to decreased resistance to gentamicin of Providencia, Serratia, indole-positive Proteus, and decreased resistance to tobramycin of Pseudomonas aueruginosa. Unrestricted use of amikacin does not necessarily lead to increase in amikacin resistance but may lead to a decrease in resistance to gentamicin and tobramycin among gram-negative organisms.",
author = "Betts, {R. F.} and Valenti, {W. M.} and Chapman, {S. W.} and T. Chonmaitree and G. Mowrer and P. Pincus and M. Messner and R. Robertson",
year = "1984",
language = "English",
volume = "100",
pages = "219--222",
journal = "Annals of Internal Medicine",
issn = "0003-4819",
publisher = "American College of Physicians",
number = "2",

}

TY - JOUR

T1 - Five-year surveillance of aminoglycoside usage in a university hospital

AU - Betts, R. F.

AU - Valenti, W. M.

AU - Chapman, S. W.

AU - Chonmaitree, T.

AU - Mowrer, G.

AU - Pincus, P.

AU - Messner, M.

AU - Robertson, R.

PY - 1984

Y1 - 1984

N2 - Because an increased incidence of nosocomial bacteremia due to gentamicin-resistant organisms occurred in our hospital, amikacin was substituted for gentamicin as the primary empiric aminoglycoside. Prospective surveillance of aminoglycoside use and of bacterial resistance to aminoglycoside was done before and after the substitution. We compared the baseline period with gentamicin was the primary aminoglycoside with the subsequent period when amikacin accounted for 81% of aminoglycoside used. During the two periods the patient population did not differ with regard to indications for aminoglycoside therapy. Among the gram-negative organisms isolated, rates of amikacin resistance during the baseline (1.1%) and usage (1.05%) periods were not significantly different (p > 0.6). Resistance to gentamicin and tobramycin during the period of amikacin use showed a statistically significant decrease (p > 0.001) due to decreased resistance to gentamicin of Providencia, Serratia, indole-positive Proteus, and decreased resistance to tobramycin of Pseudomonas aueruginosa. Unrestricted use of amikacin does not necessarily lead to increase in amikacin resistance but may lead to a decrease in resistance to gentamicin and tobramycin among gram-negative organisms.

AB - Because an increased incidence of nosocomial bacteremia due to gentamicin-resistant organisms occurred in our hospital, amikacin was substituted for gentamicin as the primary empiric aminoglycoside. Prospective surveillance of aminoglycoside use and of bacterial resistance to aminoglycoside was done before and after the substitution. We compared the baseline period with gentamicin was the primary aminoglycoside with the subsequent period when amikacin accounted for 81% of aminoglycoside used. During the two periods the patient population did not differ with regard to indications for aminoglycoside therapy. Among the gram-negative organisms isolated, rates of amikacin resistance during the baseline (1.1%) and usage (1.05%) periods were not significantly different (p > 0.6). Resistance to gentamicin and tobramycin during the period of amikacin use showed a statistically significant decrease (p > 0.001) due to decreased resistance to gentamicin of Providencia, Serratia, indole-positive Proteus, and decreased resistance to tobramycin of Pseudomonas aueruginosa. Unrestricted use of amikacin does not necessarily lead to increase in amikacin resistance but may lead to a decrease in resistance to gentamicin and tobramycin among gram-negative organisms.

UR - http://www.scopus.com/inward/record.url?scp=0021324824&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021324824&partnerID=8YFLogxK

M3 - Article

C2 - 6691664

AN - SCOPUS:0021324824

VL - 100

SP - 219

EP - 222

JO - Annals of Internal Medicine

JF - Annals of Internal Medicine

SN - 0003-4819

IS - 2

ER -